Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use

References

• Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063–1068. doi:10.1097/GME.0000000000000329
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Carbone MM, Palma P. Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. Menopause. 2016;23(10):1139–1145. doi:10.1097/GME.0000000000000675
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94. doi:10.4065/mcp.2009.0413
   PubMed Web of Science ®Google Scholar
• Palma F, Della Vecchia E, Cagnacci A, Writing Group of the AGATA study. Medical and patient attitude towards vaginal atrophy: the AGATA study. Climacteric. 2016;19(6):553–557. doi:10.1080/13697137.2016.1240770
   PubMed Web of Science ®Google Scholar
• Palma F, Volpe A, Villa P, Cagnacci A; writing group of the AGATA study. Vaginal atrophy of women in postmenopause: results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–44. doi:10.1016/j.maturitas.2015.09.001
   PubMed Web of Science ®Google Scholar
• Nappi RE, Seracchioli R, Salvatore S, Cagnacci A, Di Paolantonio T, Busacca M; investigators of the EVES Study. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;31(1):1–7.
   Google Scholar
• Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F, Gambacciani M, writing group of the ANGEL study. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019;22(1):85–89. doi:10.1080/13697137.2018.1529748
   PubMed Web of Science ®Google Scholar
• Palma F, Xholli A, Cagnacci A; as the writing group of the AGATA study. The most bothersome symptom of vaginal atrophy: evidence from the observational AGATA study. Maturitas. 2018;108:18–23. doi:10.1016/j.maturitas.2017.11.007
   PubMed Web of Science ®Google Scholar
• Palma F, Xholli A, Cagnacci A, as the writing group of the AGATA study. Management of vaginal atrophy: a real mess. Results from the AGATA study. Gynecol Endocrinol. 2017;33(9):702–707. doi:10.1080/09513590.2017.1309018
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. 2013;10(9):2232–2241. doi:10.1111/jsm.12235
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3–9. doi:10.3109/13697137.2013.871696
   PubMed Web of Science ®Google Scholar
• Nappi RE, Biglia N, Cagnacci A, Di Carlo C, Luisi S, Paoletti AM. Management diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol. 2016;32(8):602–606. doi:10.1080/09513590.2016.1183627
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799. doi:10.1111/jsm.12190
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. doi:10.1097/GME.0b013e3182a122c2
   PubMed Web of Science ®Google Scholar
• Pinkerton JAV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–753. doi:10.1097/GME.0000000000000921
   PubMed Web of Science ®Google Scholar
• Sarri G, Davies M, Lumsden MA, Guideline Development Group. Diagnosis and management of menopause: summary of NICE guidance. BMJ. 2015;12(351):h5746. doi:10.1136/bmj.h5746
   Google Scholar
• Sturdee DW, Panay N, International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509–522. doi:10.3109/13697137.2010.522875
   PubMed Web of Science ®Google Scholar
• Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal oestrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010;26(6):404–412. doi:10.3109/09513591003632258
   PubMed Web of Science ®Google Scholar
• Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–161. doi:10.3109/13697137.2015.1124259
   PubMed Web of Science ®Google Scholar
• Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat. 2016;158(1):79–90. doi:10.1007/s10549-016-3865-1
   PubMed Web of Science ®Google Scholar
• Willhite LA, O’Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21(4):464–480. doi:10.1592/phco.2001.21.issue-4
   PubMed Web of Science ®Google Scholar
• Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms a randomized clinical trial. JAMA Intern Med. 2018;178(5):681–690. doi:10.1001/jamainternmed.2018.0116
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259–263. doi:10.1016/0378-5122(95)00955-8
   PubMed Web of Science ®Google Scholar
• Diem SJ, Guthrie KA, Mitchell CM, et al. Effects of vaginal oestradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial. Menopause. 2018;25(10):1086–1093. doi:10.1097/GME.0000000000001131
   Web of Science ®Google Scholar
• Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–453. doi:10.1097/GME.0000000000001221
   PubMed Web of Science ®Google Scholar
• Rahn DD, Carberry C, Sanses TV, et al; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–1156. doi:10.1097/AOG.0000000000000526
   PubMed Web of Science ®Google Scholar
• Minkin MJ, Maamari R, Reiter S. Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health. 2013;5:133–139. doi:10.2147/IJWH.S41897
   PubMedGoogle Scholar
• FDA. Osphena. Highlights of Prescribing Information 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203505s015lbl.pdf. Accessed January 6, 2020.
   Google Scholar
• Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621. doi:10.1097/GME.0000000000001292
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Martellia V, Gava G, Seracchioli R, Meriggiola MC. Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol Endocrinol. 2017;33(12):946–950. doi:10.1080/09513590.2017.1332589
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Gava G, et al. Structure of epithelial and stromal compartments of vulvar and vaginal tissue from women with vulvo-vaginal atrophy taking ospemifene. J Sex Med. 2018;15(12):1776–1784. doi:10.1016/j.jsxm.2018.10.009
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–486. doi:10.1097/gme.0b013e3181c1ac01
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182. doi:10.3109/13697137.2013.834493
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, Bachmann GA, Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–427. doi:10.1097/gme.0b013e31826d36ba
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623–630. doi:10.1097/gme.0b013e318279ba64
   PubMed Web of Science ®Google Scholar
• Simon AJ, Altomare C, Cort S, Jiang W, Pinkerton JV. Overall safety of ospemifene in postmenopausal women from placebo-controllated phase 2 and 3 trials. J Womens Health (Larchmt). 2018;27(1):14–23. doi:10.1089/jwh.2017.6385
   PubMed Web of Science ®Google Scholar
• Murina F, Di Francesco S, Oneda S. Vulvar vestibular effects of ospemifene: a pilot study. Gynecol Endocrinol. 2018;34(7):631–635. doi:10.1080/09513590.2018.1427717
   PubMed Web of Science ®Google Scholar
• Goldstein SW, Winter AG, Goldstein I. Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study. Sex Med. 2018;6(2):154–161. doi:10.1016/j.esxm.2018.03.002
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–232. doi:10.3109/13697137.2014.954996
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Sciuga V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–669. doi:10.1080/09513590.2018.1441398
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010;116(4):876–883. doi:10.1097/AOG.0b013e3181f386bb
   PubMed Web of Science ®Google Scholar
• Simon J, Portman D, Mabey RG Jr, Ospemifene Study Group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014;77(3):274–281. doi:10.1016/j.maturitas.2013.12.005
   PubMed Web of Science ®Google Scholar
• Bruyniks N, Biglia N, Palacios S, Mueck A. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017;20(3):195–204. doi:10.1080/13697137.2017.1284780
   PubMed Web of Science ®Google Scholar
• Taras TL, Wurz GT, De Gregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77(4–5):271–279. doi:10.1016/S0960-0760(01)00066-8
   PubMed Web of Science ®Google Scholar
• Qu Q, Zheng H, Dahllund J, et al. Selective estrogen effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141(2):809–820. doi:10.1210/endo.141.2.7342
   PubMed Web of Science ®Google Scholar
• Eigeliene N, Kangas L, Hellmer C, Kauko T, Erkkola R, Ha¨rko¨nen P. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016;23:719–730. doi:10.1097/GME.0000000000000624
   PubMed Web of Science ®Google Scholar
• Senshio (ospemifene) tablets. Summary of Product Characteristics. London, UK: Shionogi Ltd; 2015.
   Google Scholar
• Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res. 2018;168:83–95. doi:10.1016/j.thromres.2018.06.014
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–137. doi:10.1056/NEJMoa062462
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–2197. doi:10.1001/jama.281.23.2189
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286–294. doi:10.1200/JCO.1991.9.2.286
   PubMed Web of Science ®Google Scholar
• Nanda S, Gupta N, Mehta HC, Sangwan K. Effect of oestrogen replacement therapy on serum lipid profile. Aust N Z J Obstet Gynaecol. 2003;43(3):213–216. doi:10.1046/j.0004-8666.2003.00068.x
   Web of Science ®Google Scholar
• Archer DF, Altomare C, Jiang W, Cort S. Ospemifene’s effects on lipids and coagulation factors: A post hoc analysis of phase 2 and 3 clinical trial data. Menopause. 2017;24(10):1167–1174. doi:10.1097/GME.0000000000000900
   PubMed Web of Science ®Google Scholar
• Bruyniks N, De Gregorio F, Gibbs T, Carroll R, Fraeman KH, Nordstrom BL. Safety of ospemifene during real-life use. J Gynecol Wom Health. 2018;9(1):1–14.
   Google Scholar
• Costantine G, Archer DF, Pollycove R, Jiang W, Altomare C, Pinkerton J. Ospemifene’s effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. Menopause. 2016;23(9):957–964. doi:10.1097/GME.0000000000000656
   Web of Science ®Google Scholar
• Vagifem summary of product characteristics. Vagifem 10 micro grams vaginal tablets. January 2015. Available from: https://www.medicines.org.uk/emc/print-document?documentId=23819. Accessed September 5, 2016.
   Google Scholar
• Faught BM, Soulban G, Yeaw J, et al. Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia. J Comp Eff Res. 2019;21:1111–1123. [Epub ahead of print].
   Google Scholar
• Imvexxy Prescribing Information. 2018. Available from: https://www.imvexxy.com/pi.pdf. Accessed December 31, 2019.
   Google Scholar
• Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413–424. doi:10.1016/j.jsxm.2017.01.010
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVESurvey. Climacteric. 2016;19(2):188–197. doi:10.3109/13697137.2015.1107039
   PubMed Web of Science ®Google Scholar